

Amendments to the Claims

This listing of the claims will replace all prior versions, and listings, of claims in this application.

Listing of Claims

1. **(Currently Amended)** A bispecific molecule comprising an anti-CR1 antibody linked to a non-neutralizing antibody that binds to a bacterial antigen or toxin ~~a pathogenic agent of an animal~~.

2.-62. **(Cancelled)**

63. **(New)** The bispecific molecule of claim 1, wherein the non-neutralizing antibody binds to Staphylococcal protein A.

64. **(New)** The bispecific molecule of claim 1, wherein the non-neutralizing antibody binds to anthrax protective antigen.

65. **(New)** The bispecific molecule of claim 1, wherein the anti-CR1 antibody is cross-linked to the non-neutralizing antibody.

66. **(New)** The bispecific molecule of claim 1, wherein at least one of the anti-CR1 antibody and the non-neutralizing antibody are monoclonal antibodies.

67. **(New)** The bispecific molecule of claim 1, wherein one or more of the antibodies is modified to reduce its immunogenicity.

68. **(New)** The bispecific molecule of claim 65, wherein one or more of the antibodies is deimmunized.

69. **(New)** The bispecific molecule of claim 1, wherein one or more of the antibodies is an antigen binding fragment of an antibody.

70. **(New)** the bispecific molecule of claim 69, wherein the antigen binding fragment is selected from the group consisting of a Fab, Fab', (Fab')₂, Fv, scFv, or scab fragment of an antibody.

71. **(New)** The bispecific molecule of claim 1, wherein one or more of the antibodies is a full length antibody.

72. **(New)** The bispecific molecule of claim 63, wherein the anti-CR1 antibody and the non-neutralizing antibody are crosslinked using a crosslinking agent.

73. **(New)** The bispecific molecule of claim 67, wherein the crosslinking agent is polyethylene glycol (PEG).

74. **(New)** The bispecific molecule of claim 1, wherein the anti-CR1 antibody is 7G9.

75. **(New)** The bispecific molecule of claim 1, wherein the anti-CR1 antibody is 19E9.

76. **(New)** A bispecific molecule comprising an anti-CR1 antibody linked to an antibody that is selected from the group consisting of: 3F3, 2F9, 3F10, 3D2, 16E11, 2C11, 6C3, and an antibody that recognizes *S. aureus* Protein A.

77. **(Withdrawn)** A method of treating or preventing a disease associated with presence of a bacterial antigen or toxin in the circulation of a subject, comprising administering to the subject a therapeutically or prophylactically effective amount of a bispecific molecule of any of claims 1 and 62-71.